Ensartinib is an anti-cancer drug developed by which pharmaceutical company?

Ensartinib is a drug produced by Chinese local pharmaceutical company Betta Pharmaceuticals (Betta Pharmaceuticals and its U.S. subsidiary As a new generation of ALK inhibitors, ensartinib was originally designed to overcome the limitations of first-generation drugs such as crizotinib in drug resistance and central nervous system penetration, improve therapeutic effects and extend patients' progression-free survival.

In the process of developing ensartinib, Betta Pharmaceuticals actively promoted the international clinical research layout of this drug, especially in the eXalt series of studies conducted globally, which achieved positive results. In the eXalt3 III phase clinical trial, ensartinib showed significantly better efficacy than crizotinib in the first-line treatment of ALKpositive NSCLC patients, especially in terms of brain metastasis control rate. These achievements have laid a solid foundation for it to be recognized by regulatory agencies in various countries.

In November 202011, ensartinib was approved by the China National Food and Drug Administration (NMPA) has been officially approved for marketing for second-line and above treatment of ALK-positive late-stage NSCLC patients. Since then, on the basis of continuously expanding indications, it was approved for the first-line treatment of ALK-positive late-stage NSCLC in 2022. More importantly, at the end of 2024, ensartinib received formal approval from the U.S. FDA and became the first ALK inhibitor to be developed globally by China and marketed in the United States, achieving a major breakthrough in the export of domestic innovative drugs overseas.

At present, ensartinib has been included in China's medical insurance directory, providing a more cost-effective treatment option for the vast number of ALK positive lung cancer patients. Through continuous R&D investment and international cooperation, Betta Pharmaceuticals has successfully created an innovative targeted drug brand with international competitiveness. Ensartinib not only represents the improvement of the innovation strength of domestic pharmaceutical companies, but also brings new treatment hope to lung cancer patients around the world.

Reference materials:https://www.drugs.com/